Targeting AMP‐activated kinase impacts hepatocellular cancer stem cells induced by long‐term treatment with sorafenib
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. HCC treatment is hindered by the frequent emergence of chemoresistance to the multikinase inhibitor sorafenib, which has been related to the presence of cancer stem cells (CSCs) that self‐renew and often escape ther...
Saved in:
| Main Authors: | Alicia Bort, Belén G. Sánchez, Pedro A. Mateos‐Gómez, Diana Vara‐Ciruelos, Nieves Rodríguez‐Henche, Inés Díaz‐Laviada |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-05-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.12488 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
by: Liu R, et al.
Published: (2024-12-01) -
Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
by: Wenjun Meng, et al.
Published: (2024-12-01) -
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
by: Young Eun Chon, et al.
Published: (2025-01-01) -
Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma
by: Eiji Higaki, et al.
Published: (2020-06-01) -
Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1
by: Jiali Zhao, et al.
Published: (2023-12-01)